NCT06765291 Behavioral Intervention for Youth to Promote Vaping Cessation
| NCT ID | NCT06765291 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Vaping |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-06-18 |
| Primary Completion | 2029-02-21 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2025-06-18 with a primary completion date of 2029-02-21.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will test the hypothesis that the QuitVaping (QV) intervention and additional texting support will improve nicotine abstinence rates in adolescents as compared to Enhanced Usual Care (EUC: education about nicotine, vaping and addiction, advice to quit vaping, referral to TIQ texting support). Approximately 400 adolescents will be randomly assigned to one of two arms (1) QuitVaping intervention plus texting support to quit vaping and (2) EUC only.
Eligibility Criteria
Inclusion Criteria: * Age 14-19 inclusive * Self-report of at least weekly nicotine vaping (or use of other non combusted nicotine products, "vaping") for the prior ≥3 months * Self-report of no regular combusted tobacco use (i.e., 5 or more days of smoke smoked tobacco use per week) prior to enrollment and exhaled CO \<10 ppm for those with an in person baseline visit * Report willingness to try to quit or reduce vaping in the next 30 days * Able to understand study procedures and read and write in English or Spanish * Have a parent or legal guardian who is able to participate in the opt out process * Competent and willing to provide written informed consent (if age 18) or assent (if under 18) Exclusion Criteria: * Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion) * Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study * Unwilling to provide saliva or urine samples * Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol
Contact & Investigator
A. Eden Evins, MD, MPH
PRINCIPAL INVESTIGATOR
Massachusetts General Hospital
Frequently Asked Questions
Who can join the NCT06765291 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, up to 19 Years, studying Vaping. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06765291 currently recruiting?
Yes, NCT06765291 is actively recruiting participants. Contact the research team at aeevins@mgh.harvard.edu for enrollment information.
Where is the NCT06765291 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06765291 clinical trial?
NCT06765291 is sponsored by Massachusetts General Hospital. The principal investigator is A. Eden Evins, MD, MPH at Massachusetts General Hospital. The trial plans to enroll 400 participants.